AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26384091 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberis aristata/Silybum marianum (B. aristata/S. marianum) 588/105 mg, 1 tablet at lunch and 1 tablet at dinner for six months
Number of subjects: 85
Study 26384091 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberis aristata/Silybum marianum (B. aristata/S. marianum)
Number of subjects: 85
Study 25300245 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (psychoeducation plus medication)
Number of subjects: 61
Study 25300245 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (medication)
Number of subjects: 61
Study 22352291 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic yoga worksite stress reduction program
Number of subjects: 239
Study 22352291 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based program
Number of subjects: 239
Study 22352291 — intervention group
Group type: COMPARATOR
Intervention: Control group (only assessment)
Number of subjects: 239
Study 19642717 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine for 2 minutes
Number of subjects: 90
Study 19642717 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine for 5 minutes
Number of subjects: 90
Study 19642717 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine for 10 minutes
Number of subjects: 90
Study 19642717 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine for 10 minutes (injection of local anesthetic)
Number of subjects: 90
Study 19642717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 17432074 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal packing for 24 hours
Number of subjects: 75
Study 17432074 — intervention group
Group type: COMPARATOR
Intervention: Nasal packing for 48 hours
Number of subjects: 75
Study 16322150 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprinted, formatted order sheets
Number of subjects: 2058
Study 16322150 — intervention group
Group type: COMPARATOR
Intervention: Regular blank order sheets
Number of subjects: 2058
Study 12504396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic hip examination
Number of subjects: 629
Study 12504396 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment alone
Number of subjects: 629
Study 9799060 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole treatment (20 mg for 4 days) with enteric-coated sodium salicylate tablets
Number of subjects: 8
Study 9799060 — intervention group
Group type: COMPARATOR
Intervention: Uncoated acetylsalicylic acid tablets
Number of subjects: 8
Study 10517036 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (20-minute sessions of shoulder, neck, head, and facial massage)
Number of subjects: 0
Study 10517036 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 0
Study 10517036 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 1677121 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal continence plug (optimum design)
Number of subjects: 10
Study 6347117 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt withdrawal (group A)
Number of subjects: 119
Study 6347117 — intervention group
Group type: COMPARATOR
Intervention: Gradual withdrawal (group G)
Number of subjects: 119
Study 30787651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Stretching with No Load (DSNL)
Number of subjects: 16
Study 30787651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Stretching with Light Load (DSLL)
Number of subjects: 16
Study 30787651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Stretching with Heavy Load (DSHL)
Number of subjects: 16
Study 30787651 — intervention group
Group type: COMPARATOR
Intervention: Static Stretching (SS)
Number of subjects: 16
Study 29961640 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (continuation)
Number of subjects: 673
Study 29961640 — intervention group
Group type: COMPARATOR
Intervention: Placebo (withdrawal)
Number of subjects: 673
Study 29961640 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (any time)
Number of subjects: 673
Study 29961640 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab vs Placebo
Number of subjects: 673
Study 25737375 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin-containing collagen sponges (2 sponges added perioperatively)
Number of subjects: 739
Study 25737375 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antimicrobial prophylaxis alone (control)
Number of subjects: 739
Study 25737375 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin-containing collagen sponges
Number of subjects: 739
Study 23683734 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stent (DES)
Number of subjects: 623
Study 23683734 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 623
Study 21948051 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde titanium elastic nail fixation (RTEN)
Number of subjects: 38
Study 21948051 — intervention group
Group type: COMPARATOR
Intervention: Reconstruction plate fixation (plate group)
Number of subjects: 38
Study 21948051 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (RTEN and plating)
Number of subjects: 38
Study 18996069 — intervention group
Group type: EXPERIMENTAL
Intervention: High-caloric food cue exposure
Number of subjects: 77
Study 18996069 — intervention group
Group type: COMPARATOR
Intervention: Low-caloric food cue exposure
Number of subjects: 77
Study 18996069 — intervention group
Group type: EXPERIMENTAL
Intervention: Food cue exposure
Number of subjects: 77
Study 17039321 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylates (5-ASA)
Number of subjects: 34
Study 15273854 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg)
Number of subjects: 29
Study 15273854 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (5 mg)
Number of subjects: 29
Study 11145818 — intervention group
Group type: EXPERIMENTAL
Intervention: Provocative discography in asymptomatic group (20 patients)
Number of subjects: 47
Study 11145818 — intervention group
Group type: EXPERIMENTAL
Intervention: Provocative discography in symptomatic group with normal psychometric scores (7 patients)
Number of subjects: 47
Study 11145818 — intervention group
Group type: EXPERIMENTAL
Intervention: Provocative discography in symptomatic group with abnormal psychometric scores (20 patients)
Number of subjects: 47
Study 11145818 — intervention group
Group type: EXPERIMENTAL
Intervention: Provocative discography in discs not treated with surgery in asymptomatic group (20 patients)
Number of subjects: 47
Study 11145818 — intervention group
Group type: EXPERIMENTAL
Intervention: Provocative discography in discs not treated with surgery in symptomatic group with normal psychometric testing (7 patients)
Number of subjects: 47
Study 11145818 — intervention group
Group type: EXPERIMENTAL
Intervention: Provocative discography in discs not treated with surgery in symptomatic group with abnormal psychometric testing (13 patients)
Number of subjects: 47
Study 11145818 — intervention group
Group type: COMPARATOR
Intervention: Control group (symptomatic patients)
Number of subjects: 47
Study 8976470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 8976470 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0
Study 1633070 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg daily
Number of subjects: 9
Study 1633070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg twice daily
Number of subjects: 9
Study 1633070 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 9
Study 6428911 — intervention group
Group type: EXPERIMENTAL
Intervention: Ouabain 0.5 mg i.v.
Number of subjects: 18
Study 6428911 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin 0.8 mg sublingual
Number of subjects: 18
Study 6428911 — intervention group
Group type: EXPERIMENTAL
Intervention: Ouabain 12 mg sublingual
Number of subjects: 18
Study 31542806 — intervention group
Group type: EXPERIMENTAL
Intervention: 840 mg every 2 weeks (q2w)
Number of subjects: 0
Study 31542806 — intervention group
Group type: EXPERIMENTAL
Intervention: 1680 mg every 4 weeks (q4w)
Number of subjects: 0
Study 31542806 — intervention group
Group type: COMPARATOR
Intervention: 1200 mg every 3 weeks (q3w)
Number of subjects: 0
Study 31542806 — intervention group
Group type: COMPARATOR
Intervention: Maximum assessed dose (MAD; 20 mg/kg q3w)
Number of subjects: 0
Study 30532195 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES on tibialis anterior muscle (NMES-TA)
Number of subjects: 25
Study 30532195 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES on medial gastrocnemius muscle (NMES-MG)
Number of subjects: 25
Study 30532195 — intervention group
Group type: COMPARATOR
Intervention: Control group (range of motion and stretching exercises)
Number of subjects: 25
Study 27845159 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Heating System (THS) 2.2
Number of subjects: 0
Study 27845159 — intervention group
Group type: COMPARATOR
Intervention: Continuous use of non-menthol combustible cigarettes (CC arm)
Number of subjects: 0
Study 27845159 — intervention group
Group type: COMPARATOR
Intervention: Smoking abstinence (SA arm)
Number of subjects: 0
Study 24568910 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Number of subjects: 214
Study 24568910 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 214
Study 21335358 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of MK-0249 (H3RIA)
Number of subjects: 18
Study 21335358 — intervention group
Group type: COMPARATOR
Intervention: Stable alcohol level (0.6 g L(‐1))
Number of subjects: 18
Study 21335358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 20374986 — intervention group
Group type: EXPERIMENTAL
Intervention: Online multifamily group program for relatives of persons with schizophrenia
Number of subjects: 26
Study 20374986 — intervention group
Group type: COMPARATOR
Intervention: Customary care
Number of subjects: 26
Study 18057478 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose candy (vitamin A 1000 IU and 14 mg elemental iron) daily
Number of subjects: 410
Study 18057478 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose candy for 3 days a week
Number of subjects: 410
Study 18057478 — intervention group
Group type: EXPERIMENTAL
Intervention: Half dose candy (vitamin A 500 IU and 7 mg elemental iron) daily
Number of subjects: 410
Study 18057478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study 16327947 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEP alone (Flector Tissugel)
Number of subjects: 10
Study 16327947 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEP/heparin (Flector Tissugel Heparin)
Number of subjects: 10
Study 16327947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12139912 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife examination
Number of subjects: 826
Study 12139912 — intervention group
Group type: COMPARATOR
Intervention: Junior paediatrician examination
Number of subjects: 826
Study 12139912 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of health-care issues during examination
Number of subjects: 826
Study 12139912 — intervention group
Group type: EXPERIMENTAL
Intervention: Current maternal depressive mood
Number of subjects: 826
Study 9829113 — intervention group
Group type: EXPERIMENTAL
Intervention: Translucent (frosted) diffuser
Number of subjects: 20
Study 9829113 — intervention group
Group type: EXPERIMENTAL
Intervention: +1.50 D (fogging) lens
Number of subjects: 20
Study 9829113 — intervention group
Group type: EXPERIMENTAL
Intervention: White opaque occluder
Number of subjects: 20
Study 9829113 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular summation ratios
Number of subjects: 20
Study 9809958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 2% dodecafluoropentane emulsion (EchoGen)
Number of subjects: 40
Study 9809958 — intervention group
Group type: COMPARATOR
Intervention: No contrast (baseline assessment)
Number of subjects: 40
Study 2535086 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia with bupivacaine 0.125% and sufentanil 0.83 micrograms.ml‐1
Number of subjects: 20
Study 2535086 — intervention group
Group type: COMPARATOR
Intervention: Intravenous peroperative and on-demand intramuscular postoperative analgesia with nicomorphine 0.2 mg.kg‐1
Number of subjects: 20
Study 341650 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine
Number of subjects: 30
Study 341650 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 30
Study 31407810 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Nexvax2 (900 µg)
Number of subjects: 14
Study 31407810 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Nexvax2 (900 µg)
Number of subjects: 14
Study 31407810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 28918556 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 119
Study 28918556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 26298520 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 hour of simulation training
Number of subjects: 17
Study 26298520 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (control group)
Number of subjects: 17
Study 23526949 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd63-MVA ME-TRAP
Number of subjects: 46
Study 21471773 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (initial dose of 50 mg, adjustable to 25 or 100 mg)
Number of subjects: 202
Study 21471773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 21471773 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 202
Study 19011931 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective pharmacological inhibition of the norepinephrine transporter (NET)
Number of subjects: 11
Study 19011931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 16158312 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral topotecan (1.2 mg/m2) once a day for 10 days
Number of subjects: 90
Study 16158312 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral topotecan (1.2 mg/m2) twice a day for 5 days
Number of subjects: 90
Study 16158312 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice a day dosing of topotecan
Number of subjects: 90
Study 16158312 — intervention group
Group type: EXPERIMENTAL
Intervention: Once a day dosing of topotecan
Number of subjects: 90
Study 15309247 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 15309247 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 0
Study 15309247 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 0
Study 15309247 — intervention group
Group type: EXPERIMENTAL
Intervention: Optional regimens for low-risk and high-risk patients
Number of subjects: 0
Study 11281598 — intervention group
Group type: EXPERIMENTAL
Intervention: Hughes tarsoconjunctival advancement combined with oblique medial and lateral periosteal flaps
Number of subjects: 8
Study 9394980 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidic hot-spring bathing (10-min bath at 42 degrees C, twice daily)
Number of subjects: 70
Study 8071832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (400 mg every 12 h for 8 days)
Number of subjects: 0
Study 8071832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten metabolite (trans-isomer)
Number of subjects: 0
Study 3310745 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 22
Study 3310745 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 22
Study 3310745 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 22
Study 29288545 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin (10 mg twice a day)
Number of subjects: 137
Study 29288545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 29288545 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Number of subjects: 137
Study 29288545 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin and Placebo
Number of subjects: 137
Study 26987876 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-week multi-component intervention including the Sapere method, cooked lunches, meal principles, and parental involvement.
Number of subjects: 18
Study 26987876 — intervention group
Group type: COMPARATOR
Intervention: Control group continued usual practices.
Number of subjects: 18
Study 25718355 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-month dual-antiplatelet therapy (DAPT) in ACS patients
Number of subjects: 1970
Study 25718355 — intervention group
Group type: COMPARATOR
Intervention: 6-month dual-antiplatelet therapy (DAPT) in ACS patients
Number of subjects: 1970
Study 25718355 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-month dual-antiplatelet therapy (DAPT) in SCAD patients
Number of subjects: 1970
Study 25718355 — intervention group
Group type: COMPARATOR
Intervention: 6-month dual-antiplatelet therapy (DAPT) in SCAD patients
Number of subjects: 1970
Study 22323747 — intervention group
Group type: EXPERIMENTAL
Intervention: varenicline (1 mg twice daily for 4 weeks after 4 weeks of titration)
Number of subjects: 20
Study 22323747 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 20528570 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (rosiglitazone and pioglitazone)
Number of subjects: 0
Study 20528570 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0
Study 20528570 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptives
Number of subjects: 0
Study 19041501 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA light exposure with dry tattooing
Number of subjects: 20
Study 19041501 — intervention group
Group type: COMPARATOR
Intervention: UVA light exposure without dry tattooing
Number of subjects: 20
Study 15983534 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavones (5 mg/kg body weight)
Number of subjects: 10
Study 15983534 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg) plus isoflavones (5 mg/kg body weight)
Number of subjects: 10
Study 15983534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12027856 — intervention group
Group type: EXPERIMENTAL
Intervention: Group LBH (2.5 ml lignocaine 2%, 2.5 ml bupivacaine 0.5%, 15 IU hyaluronidase/ml and 0.125 ml isotonic saline)
Number of subjects: 60
Study 12027856 — intervention group
Group type: COMPARATOR
Intervention: Group LB (2.5 ml lignocaine 2%, 2.5 ml bupivacaine 0.5% and 0.125 ml isotonic saline)
Number of subjects: 60
Study 12027856 — intervention group
Group type: COMPARATOR
Intervention: Group LBpH (2.5 ml lignocaine 2%, 2.5 ml bupivacaine 0.5% and 0.125 ml sodium bicarbonate 8.4%)
Number of subjects: 60
Study 12027856 — intervention group
Group type: COMPARATOR
Intervention: Group LBHpH (2.5 ml lignocaine 2%, 2.5 ml bupivacaine 0.5%, 15 IU hyaluronidase/ml and 0.125 ml sodium bicarbonate 8.4%)
Number of subjects: 60
Study 10709307 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation consisting of pressure on acupoints (P)
Number of subjects: 24
Study 10709307 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation consisting of stroking along the meridians (S)
Number of subjects: 24
Study 10709307 — intervention group
Group type: COMPARATOR
Intervention: Control stimulation (C)
Number of subjects: 24
Study 7795311 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion
Number of subjects: 38
Study 7795311 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile perfusion
Number of subjects: 38
Study 1822997 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ISD (isosorbide dinitrate)
Number of subjects: 23
Study 1822997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 111104 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of slow-release xantinol nicotinate (XN) twice daily for 12 weeks
Number of subjects: 80
Study 111104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 31351832 — intervention group
Group type: EXPERIMENTAL
Intervention: Venefit
Number of subjects: 180
Study 31351832 — intervention group
Group type: EXPERIMENTAL
Intervention: RFITT
Number of subjects: 180
Study 31351832 — intervention group
Group type: COMPARATOR
Intervention: EVRF
Number of subjects: 180
Study 31351832 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 180
Study 28257982 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Search (VS) Attentional Bias Modification (ABM)
Number of subjects: 108
Study 28257982 — intervention group
Group type: COMPARATOR
Intervention: Visual Search (VS) Placebo-Training
Number of subjects: 108
Study 28257982 — intervention group
Group type: COMPARATOR
Intervention: No-Training Control Group
Number of subjects: 108
Study 26229189 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician provision of early medical abortion
Number of subjects: 884
Study 26229189 — intervention group
Group type: COMPARATOR
Intervention: Nurse provision of early medical abortion
Number of subjects: 884
Study 23260628 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% (30mL)
Number of subjects: 140
Study 23260628 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 140
Study 20545775 — intervention group
Group type: EXPERIMENTAL
Intervention: DioxiDent mouthrinse
Number of subjects: 60
Study 20545775 — intervention group
Group type: EXPERIMENTAL
Intervention: Corsodyl mouthrinse
Number of subjects: 60
Study 20545775 — intervention group
Group type: COMPARATOR
Intervention: Tissue conditioner
Number of subjects: 60
Study 19819667 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous morphine with 150U of recombinant human hyaluronidase (rHuPH20)
Number of subjects: 18
Study 19819667 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous morphine without recombinant human hyaluronidase (rHuPH20)
Number of subjects: 18
Study 19819667 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 18
Study 16470116 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV genotype 3
Number of subjects: 395